Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

Frederik Novak, Hamza Mahmood Bajwa, John Eugenio Coia, Anna Christine Nilsson, Christian Nielsen, Dorte K Holm, Kamilla Østergaard, Mathilde Vilhelmine Miller Hvidt, Keld-Erik Byg, Isik S Johansen, Kristen Mittl, William Rowles, Scott S Zamvil, Riley Bove, Joseph J Sabatino, Tobias Sejbaek*

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

16 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses'. Together they form a unique fingerprint.

Medicine and Dentistry

Immunology and Microbiology